Share on StockTwits

BIND Therapeutics (NASDAQ:BIND) announced its earnings results on Thursday. The company reported ($0.51) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.60) by $0.09, StockRatingsNetwork reports. The company had revenue of $2.46 million for the quarter, compared to the consensus estimate of $2.20 million.

Shares of BIND Therapeutics (NASDAQ:BIND) remained flat at $9.06 during trading on Thursday. The stock had a trading volume of 12,349 shares. BIND Therapeutics has a 1-year low of $8.00 and a 1-year high of $15.89. The stock has a 50-day moving average of $10.51 and a 200-day moving average of $11.03. The company’s market cap is $149.0 million.

On the ratings front, analysts at Credit Suisse reiterated an “outperform” rating on shares of BIND Therapeutics in a research note on Thursday, July 3rd. They now have a $20.00 price target on the stock, down previously from $21.00.

BIND Therapeutics Inc is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.